Detalles de la búsqueda
1.
Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Oncology;
102(4): 318-326, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37778345
2.
Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis.
BMC Cancer;
22(1): 1228, 2022 Nov 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36443704
3.
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Oncologist;
25(8): 702-711, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32386255
4.
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors.
J Formos Med Assoc;
117(4): 326-331, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28499641
5.
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.
Curr Oncol Rep;
19(1): 4, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28138934
6.
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.
J Biomed Sci;
23(1): 86, 2016 Dec 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27912760
7.
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Curr Opin Oncol;
27(2): 94-101, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25611025
8.
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma.
Nat Commun;
14(1): 2781, 2023 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37188668
9.
A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study).
Cancers (Basel);
15(20)2023 Oct 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37894366
10.
Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis.
Clin Cancer Res;
28(8): 1560-1571, 2022 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35046059
11.
CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer.
Anticancer Res;
41(3): 1231-1242, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33788714
12.
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M-Positive NSCLC.
JTO Clin Res Rep;
2(1): 100099, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34589970
13.
Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
J Thorac Oncol;
15(1): 50-61, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31557536
14.
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
Eur J Cancer;
124: 110-122, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31760310
15.
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients.
Ther Adv Med Oncol;
11: 1758835919890286, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31803256
16.
Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?
Expert Opin Pharmacother;
19(8): 851-864, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29726292
17.
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan.
J Cancer;
9(10): 1813-1820, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29805708
18.
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Lung Cancer;
110: 7-13, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28676222
19.
Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis.
Med Oncol;
34(8): 143, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28726044
20.
Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC.
J Thorac Oncol;
16(9): 1426-1428, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34425993